| Name | Title | Contact Details |
|---|
Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
ImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company`s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. We are applying our science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
Victor International Mktg Inc is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mirus Bio is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with our next-generation, targeted antibody drug conjugates (ADCs). With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, we are working to address significant unmet medical needs and improve outcomes for those with difficult-to-treat hematological cancers and solid tumors. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial), and the San Francisco Bay Area (CMC). Our highly skilled global team is committed to confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.